Pathology Research International results,” Journal of Clinical Oncology, vol. 28, supplement, 2010, ASCO Annual Meeting, abstract no. e14083. [89] M. Di Salvatore, A. Inno, A. Orlandi et al., “KRAS and BRAF mutational status and PTEN, cMET, and IGF1R expression as predictive markers of response to cetuximab plus chemotherapy in metastatic colorectal cancer (mCRC),” Journal of Clinical Oncology, vol. 28, supplement, 2010, ASCO Annual Meeting, abstract no. e14065. [90] S. R. Alberts, D. J. Sargent, T. C. Smyrk et al., “Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup Phase III Trial N0147,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, ASCO Annual Meeting, abstract no. CRA3507. [91] R. M. Goldberg, D. J. Sargent, and S. N. Thibodeau, “Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, ASCO Annual Meeting, abstract no. 3508. [92] J. Giralt, M. de las Heras, L. Cerezo et al., “The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis,” Radio- therapy and Oncology, vol. 74, no. 2, pp. 101–108, 2005. [93] J. S. Kim, J. M. Kim, S. Li et al., “Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoper- ative chemoradiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 1, pp. 195–200, 2006. [94] K. Y. Chung, B. Minsky, D. Schrag et al., “Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-ﬂuorouracil and pelvic radiation in patients with local- regionally advanced rectal cancer,” Journal of Clinical Oncol- ogy, vol. 24, no. 18, supplement, 2006, abstract no. 3560. [95] R. D. Hofheinz, K. Horisberger, C. Woernle et al., “Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 5, pp. 1384–1390, 2006. [96] J. P. Machiels, C. Sempoux, P. Scalliet et al., “Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer,” Annals of Oncology, vol. 18, no. 4, pp. 738–744, 2007. [97] C. Ro¨del, D. Arnold, M. Hipp et al., “Phase I-II Trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 70, no. 4, pp. 1081–1086, 2008. [98] K. Horisberger, A. Treschl, S. Mai et al., “Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial,” International Journal of Radiation Oncology Biology Physics, vol. 74, no. 5, pp. 1487–1493, 2009. [99] F. Bertolini, S. Chiara, C. Bengala et al., “Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 73, no. 2, pp. 466– 472, 2009. [100] V. Velenik, J. Ocvirk, I. Oblak, and F. Anderluh, “A phase II study of cetuximab, capecitabine and radiotherapy in neoad- juvant treatment of patients with locally advanced resectable 11 rectal cancer,” European Journal of Surgical Oncology, vol. 36, no. 3, pp. 244–250, 2010. [101] C. Bengala, S. Bettelli, F. Bertolini et al., “Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer,” Annals of Oncology, vol. 20, no. 3, pp. 469–474, 2009. [102] A. Debucquoy, K. Haustermans, A. Daemen et al., “Molec- ular response to cetuximab and eﬃcacy of preoperative cetuximab-based chemoradiation in rectal cancer,” Journal of Clinical Oncology, vol. 27, no. 17, pp. 2751–2757, 2009. [103] K. J. Williams, B. A. Telfer, I. J. Stratford, and S. R. Wedge, “ZD1839 (’Iressa’), a speciﬁc oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model,” British Journal of Cancer, vol. 86, no. 7, pp. 1157–1161, 2002. [104] V. Valentini, A. De Paoli, M. A. Gambacorta et al., “Infusional 5-ﬂuorouracil and ZD1839 (Geﬁtinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL/0092),” International Journal of Radiation Oncology Biology Physics, vol. 72, no. 3, pp. 644–649, 2008. [105] L. S. Blaszkowsky, T. S. Hong, A. X. Zhu et al., “A phase I/II study of bevacizumab, erlotinib, and 5-ﬂuorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer,” Journal of Clinical Oncology, vol. 27, no. 15, supplement, p. 194S, 2009, abstract no. 4106.